https://orcid.org/0009-0009-2041-8707
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background: Acute myeloid leukemia (AML) is a challenging disease with high rates of recurrence. The role of the cancer-related gene GRHL2 in AML has not been widely studied. Methods: Peripheral blood samples were collected from 73 AML patients and 68 healthy controls. Droplet digital PCR was used to detect GRHL2 methylation levels to explore the value of GRHL2 methylation in the diagnosis, treatment response and prognosis of AML. Result: GRHL2 methylation was significantly increased in AML patients (p < 0.01), with high diagnostic accuracy (area under the curve: 0.848; p < 0.001). GRHL2 methylation was correlated with chemotherapy response (p < 0.05) and is an independent prognostic factor for AML (p < 0.05). Conclusion: GRHL2 methylation is expected to serve as a biomarker for diagnosing AML patients and predicting prognosis.
Supplementary data
To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/epi-2023-0406
Author contributions
J Hua was the main contributor in manuscript writing. M Chu conducted ddPCR testing on peripheral blood samples of AML patients. L Xuan and F Bo designed the research framework and conducted statistical analysis of the data in the article. C Wang, H Zhang, J Luan, Q Li, T Xiao and C Zhu analyzed and interpreted patient data related to AML.
Financial disclosure
This work was supported by National Natural Science Foundation of China (grant no. 81702884), Natural Science Foundation of Shandong Province (grant nos. ZR2022MH272 and ZR2023QH115), Medicine and Health Science and Technology Foundation of Shandong Province (grant no. 202111000399 and 202202080721), Traditional Chinese Medicine Science and Technology Foundation of Shandong Province (grant no. M-2022122). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Competing interests disclosure
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Writing disclosure
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
The authors state that they confirm that this research study has obtained ethics approval from the Ethics Committee of Liaocheng People’s Hospital (no. 2023137). All participants involved in the study provided written informed consent to participate. The research procedures and protocols followed ethical guidelines and regulations, ensuring the privacy, confidentiality and rights of the participants.
Data sharing statement
The data that support the findings of this study are available from the authors but restrictions apply to the availability of these data, which were used under license from the Liaocheng People’s Hospital for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission from the Ethics Committee of Liaocheng People’s Hospital.